NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$16.91
-1.08 (-6.00%)
Close of Nov 06, 2026 · end-of-day data
TNDM 8-K filings in 2024
Every material Form 8-K Tandem Diabetes Care filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tandem Diabetes Care reported third quarter 2024 GAAP sales of $244.0 million, up 31% from a year earlier, and raised its 2024 non-GAAP sales guidance to $903 million to $910 million. The net loss narrowed to $23.3 million from $33.0 million, which supports the company's revenue growth and improving loss trend for shareholders.
Q3 2024 GAAP sales were $244.0 million, up 31% from $185.6 million; non-GAAP sales were $242.9 million, up 25%.
GAAP net loss was $23.3 million, or $0.35 per share, compared with $33.0 million, or $0.51 per share, a year earlier.
Full-year 2024 non-GAAP sales guidance is now approximately $903 million to $910 million, with U.S. sales of $645 million to $650 million.
Non-GAAP gross margin guidance of about 51% and Adjusted EBITDA margin guidance of breakeven were reaffirmed.
Tandem Diabetes Care reported second-quarter 2024 GAAP sales up 13% to $221.9 million and a narrower GAAP net loss of $30.8 million, compared with $35.8 million a year earlier. The company also raised its full-year 2024 non-GAAP sales estimate to approximately $885 million to $892 million, which it attributes to recent product launches and customer retention. The company still reported a loss, and its Tandem Choice program adds accounting complexity to GAAP comparisons.
Q2 2024 GAAP sales were $221.9 million, up 13% from $195.9 million in Q2 2023; non-GAAP sales were $221.8 million, up 12%.
GAAP net loss was $30.8 million, or $0.47 per share, versus $35.8 million, or $0.55 per share, in Q2 2023.
Full-year 2024 non-GAAP sales are now estimated at approximately $885 million to $892 million, with third-quarter sales of $222 million to $225 million.
Non-GAAP gross margin is estimated at approximately 51% for the full year, and Adjusted EBITDA margin at breakeven.
Tandem Diabetes Care appointed Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. He previously held president and general manager roles at Envista Holdings, Qualcomm Life, Becton Dickinson and ResMed, according to the filing. The filing sets his base salary at $450,203.73 and a target annual bonus of 60% of base salary, and it includes change-of-control severance terms.
Appointment effective June 21, 2024; the Board approved it on June 19, 2024
Offer letter dated June 10, 2024 sets base salary of $450,203.73
Target annual bonus of 60% of base salary; target long-term incentive award of 400% of base salary in RSUs
Prior role: President of Diagnostics and Digital Solutions at Envista Holdings, February 2020 to June 2023
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tandem Diabetes Care filing is on SEC EDGAR ↗. 8-K briefs of other companies →